ISSN 1016-5169 | E-ISSN 1308-4488
pdf
An epidemiological study to evaluate the use of vitamin K antagonists and new oral anticoagulants among non-valvular atrial fibrillation patients in Turkey- AFTER*-2 study design [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2015; 43(2): 169-177 | DOI: 10.5543/tkda.2015.35984

An epidemiological study to evaluate the use of vitamin K antagonists and new oral anticoagulants among non-valvular atrial fibrillation patients in Turkey- AFTER*-2 study design

Faruk Ertas1, Hasan Kaya1, Abdulkadir Yildiz1, Vedat Davutoglu2, Abdulkadir Kiris3, Lale Dinc4, Habibe Kafes5, Anil Avci6, Bekir Calapkorur7, Gokhan Ertas8, Mehmet Gul9, Nuray Kahraman Ay10, Serkan Bulur11, Mine Durukan12
1Department of Cardiology, Dicle University Faculty of Medicine, Diyarbakir, Turkey.
2Department of Cardiology, Gaziantep University Faculty of Medicine, Gaziantep, Turkey
3Department of Cardiology, Karadeniz Technique University Faculty of Medicine, Trabzon, Turkey
4Department of Cardiology, Diskapi Training and Research Hospital, Ankara, Turkey
5Department of Cardiology, Yuksek Ihtisas Training and Research Hospital, Ankara, Turkey
6Department of Cardiology, Kosuyolu Training and Research Hospital, İstanbul, Turkey
7Department of Cardiology, Erciyes University Faculty of Medicine, Kayseri, Turkey
8Dept. of Cardiology, Siyami Ersek Training and Research Hospital, Istanbul, Turkey
9Dept. of Cardiology, Mehmet Akif Ersoy Training and Research Hospital, Istanbul, Turkey
10Dept. of Cardiology, Bezmialem Foundation University Faculty of Medicine, Istanbul, Turkey
11Dept. of Cardiology, Medeniyet University Faculty of Medicine, Istanbul, Turkey
12Dept. of Cardiology, Mardin State Hospital, Mardin, Turkey


OBJECTIVES
Atrial fibrillation (AF) is one of the most common causes of preventable ischemic stroke and is related to increased cardiovascular morbidity and mortality. There is a lack of data in Turkey on the use of new oral anticoagulants (NOACs), and time in therapeutic INR range (TTR) in vitamin K antagonist users and AF management modality. In this multi-center trial, we aimed to analyze, follow and evaluate the epidemiological data in non-valvular AF patients.

STUDY DESIGN
Four thousand one hundred consecutive adult patients from 42 centers with at least one AF attack identified on electrocardiography will be included in the study. Patients with rheumatic mitral valve stenosis and prosthetic valve disease will be excluded from the study. At the end of one year, the patients will be evaluated in terms of major cardiac end points (death, transient ischemic attack, stroke, systemic thromboembolism, major bleeding and hospitalization).

RESULTS
First results are expected in June 2015. Data about major cardiovascular end-points will be available in January 2016.

CONCLUSION
The rates and kind of oral anticoagulant use, TTR in vitamin K antagonist users and main management modality applied in non-valvular AF patients will be determined by AFTER-2 study. In addition, the rate of major adverse events (MACEs) and the independent predictors of these MACEs will be detected (AFTER-2 Study ClinicalTrials.gov number, NCT02354456.).

Keywords: Anticoagulant agent, atrial fibrillation/epidemiology; drug utilization; electrocardiography; international normalized ratio; warfarin

How to cite this article
Faruk Ertas, Hasan Kaya, Abdulkadir Yildiz, Vedat Davutoglu, Abdulkadir Kiris, Lale Dinc, Habibe Kafes, Anil Avci, Bekir Calapkorur, Gokhan Ertas, Mehmet Gul, Nuray Kahraman Ay, Serkan Bulur, Mine Durukan. An epidemiological study to evaluate the use of vitamin K antagonists and new oral anticoagulants among non-valvular atrial fibrillation patients in Turkey- AFTER*-2 study design. Turk Kardiyol Dern Ars. 2015; 43(2): 169-177

Corresponding Author: Abdulkadir Yildiz, Türkiye
Manuscript Language: English


Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
0.22
SCImago Journal Rank: 0.348

Quick Search



Copyright © 2024 Archives of the Turkish Society of Cardiology



Kare Publishing is a subsidiary of Kare Media.